MedTrace Logo

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.

Conditions

Interventions

DRUG

Afatinib/Dacomitinib

Second-generation EGFR-inhibitors

DRUG

Osimertinib

Third-generation EGFR-inhibitor

Sponsors & Collaborators

  • Swedish Lung Cancer Study Group

    collaborator NETWORK

  • Region Skane

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-21
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06486142 on ClinicalTrials.gov